Emma Bagshaw1, Daniel Kuessner2, Jan Posthumus2, Cesar Escrig3, Michael Blackney1, Sebastian Marcel Heimann4, Oliver Andreas Cornely4,5. 1. Covance Market Access, Covance, London, UK. 2. Global Market Access and Health Economics, Basilea Pharmaceutica International Ltd, Basel, Switzerland. 3. Global Medical Affairs, Basilea Pharmaceutica International Ltd, Basel, Switzerland. 4. Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 5. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
Abstract
AIM: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored treatment costs with ISAV versus liposomal AMB followed by posaconazole. MATERIALS & METHODS: As a matched case-control analysis showed similar efficacy for ISAV and AMB, a cost-minimization approach was taken. Direct costs - drug acquisition, monitoring and administration, and hospitalization costs - were estimated from the National Health Service perspective. RESULTS: Per-patient costs for ISAV and liposomal AMB + posaconazole were UK£26,810 and UK£41,855, respectively, with savings primarily driven by drug acquisition and hospitalization costs. CONCLUSION: ISAV may reduce costs compared with standard mucormycosis therapy.
AIM: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored treatment costs with ISAV versus liposomal AMB followed by posaconazole. MATERIALS & METHODS: As a matched case-control analysis showed similar efficacy for ISAV and AMB, a cost-minimization approach was taken. Direct costs - drug acquisition, monitoring and administration, and hospitalization costs - were estimated from the National Health Service perspective. RESULTS: Per-patient costs for ISAV and liposomal AMB + posaconazole were UK£26,810 and UK£41,855, respectively, with savings primarily driven by drug acquisition and hospitalization costs. CONCLUSION: ISAV may reduce costs compared with standard mucormycosis therapy.
Authors: José Ramón Azanza; Santiago Grau; Lourdes Vázquez; Pablo Rebollo; Carmen Peral; Alejandra López-Ibáñez de Aldecoa; Vanessa López-Gómez Journal: Mycoses Date: 2020-10-30 Impact factor: 4.377